We are live on ! Find out more
CS

Credit Suisse Portfolio holdings

AUM $104B
1-Year Est. Return 34.76%
This Fund
S&P 500
This Quarter Est. Return
+8.7%
1 Year Est. Return
+34.76%
3 Year Est. Return
+49.35%
5 Year Est. Return
+181.01%
10 Year Est. Return
+395.52%
AUM
$189B
AUM Growth
-$6.65B
Cap. Flow
-$21B
Cap. Flow %
-11.12%
Top 10 Hldgs %
16.9%
Holding
4,784
New
635
Increased
1,494
Reduced
2,137
Closed
388

Sector Composition

Rank Sector Weight
1 Technology 14.66%
2 Healthcare 11.06%
3 Financials 8.17%
4 Consumer Discretionary 8.09%
5 Communication Services 6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SFT
4226
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
$93K ﹤0.01%
1,077
-3,907
-78% -$313K
BURU.WS
4227
DELISTED
Nuburu, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
BURU.WS
$91K ﹤0.01%
+68,243
New +$76.8K
DNN icon
4228
CALL
Denison Mines
DNN
$2.54B
$89K ﹤0.01%
75,000
AUUD
4229
Auddia
AUUD
$5.47M
$88K ﹤0.01%
+5
New +$46.5K
ALB icon
4230
CALL
Albemarle
ALB
$13.9B
$84K ﹤0.01%
+500
New +$80.7K
RVLP
4231
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$84K ﹤0.01%
+27,966
New +$85.6K
GAB icon
4232
Gabelli Equity Trust
GAB
$1.75B
$83K ﹤0.01%
+12,100
New +$84.8K
BDRX
4233
Biodexa Pharmaceuticals
BDRX
$1.19M
0
LYTS icon
4234
LSI Industries
LYTS
$859M
$81K ﹤0.01%
+10,104
New +$84.8K
NTLA icon
4235
CALL
Intellia Therapeutics
NTLA
$1.49B
$81K ﹤0.01%
+500
New +$38.9K
LKCO
4236
DELISTED
Luokung Technology Corp Ordinary Shares
LKCO
$78K ﹤0.01%
+128
New +$47.2K
SEEL
4237
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$77K ﹤0.01%
+8
New +$131K
AFRM icon
4238
PUT
Affirm
AFRM
$23.9B
$74K ﹤0.01%
+1,100
New +$70.2K
PLM
4239
DELISTED
PolyMet Mining Corp.
PLM
$73K ﹤0.01%
+20,106
New +$63.2K
SFT
4240
CALL
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
$68K ﹤0.01%
+790
New +$63.3K
FACA.WS
4241
DELISTED
Figure Acquisition Corp. I Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
FACA.WS
$68K ﹤0.01%
+48,120
New +$62.9K
ARVLW
4242
DELISTED
Arrival Warrant
ARVLW
$68K ﹤0.01%
+14,244
New +$83.4K
AXSM icon
4243
PUT
Axsome Therapeutics
AXSM
$11.2B
$67K ﹤0.01%
+1,000
New +$60K
DHX icon
4244
DHI Group
DHX
$182M
$66K ﹤0.01%
+19,210
New +$60.9K
SOS
4245
SOS Limited
SOS
$16.6M
$65K ﹤0.01%
+26
New +$76.2K
HII icon
4246
PUT
Huntington Ingalls Industries
HII
$12.9B
$62K ﹤0.01%
+300
New +$63.9K
RACE icon
4247
PUT
Ferrari
RACE
$69.2B
$62K ﹤0.01%
+300
New +$62.6K
AEI icon
4248
Alset
AEI
$39.7M
$60K ﹤0.01%
+526
New +$73.8K
VAL.WS icon
4249
Valaris Ltd Warrants
VAL.WS
$633M
$55K ﹤0.01%
+20,881
New +$45.2K
AMRN
4250
Amarin Corp
AMRN
$299M
$52K ﹤0.01%
593
+20
+3% +$1.96K

Similar funds

Credit Suisse's Q2 2021 Portfolio in Review

As of Q2 2021, Credit Suisse held 4,784 positions worth $189B, down 3.4% from $195B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Credit Suisse withdrew a net $21B in Q2 2021, closing 388 positions and reducing 2,137 holdings. Its most notable exit was INPHI CORPORATION, an estimated $356M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Credit Suisse opened a new position in Recursion Pharmaceuticals worth $52.9M.

  • Credit Suisse's largest Q2 2021 buy was Recursion Pharmaceuticals: 1,449,585 shares worth $52.9M.
  • Credit Suisse added most to iShares Core S&P 500 ETF in Q2 2021, an estimated $826M increase.
  • Credit Suisse's biggest Q2 2021 reduction was Alibaba, cutting an estimated $1.27B.
  • Credit Suisse fully exited INPHI CORPORATION in Q2 2021, selling an estimated $356M.
  • Credit Suisse's ten largest holdings make up 17% of its $189B portfolio in Q2 2021.
  • Credit Suisse opened 635 new positions and closed 388 in Q2 2021.
  • Credit Suisse's portfolio value fell 3.4% quarter-over-quarter to $189B.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.